New hope for stage III lung cancer: treatments tailored to your genes

NCT ID NCT05170204

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tests different treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Participants are grouped by specific genetic markers (biomarkers) to see which therapy works best for their cancer type. The main goal is to see how long the cancer stays under control. About 68 people will take part in this phase 3 trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea
Asst Grande Ospedale Metropolitano Niguarda

Milan, Lombardy, 20162, Italy
Centre Francois Baclesse

Caen, 14000, France
Centre Leon Berard

Lyon, 69008, France
Chonnam National University Hwasun Hospital

Jeollanam-do, 58128, South Korea
Christie Hospital Nhs Trust

Manchester, M2O 4BX, United Kingdom
Dolno?l?skie Centrum Chorób P?uc we Wroc?awiu

Wroc?aw, 53-439, Poland
Faculty of Med. Siriraj Hosp.

Bangkok, 10700, Thailand
Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo

Bogota, D.C., 110131, Colombia
Helios Klinikum Emil von Behring GmbH

Berlin, 14165, Germany
Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
Hopital Nord

Marseille, 13915, France
Hospital Civil de Guadalajara Fray Antonio Alcalde

Guadalajara, Jalisco, 44280, Mexico
Hospital Universitario San Ignacio

Bogotá, 000472, Colombia
Hospital de Cancer de Barretos

Barretos, São Paulo, 14784-400, Brazil
Hunan Cancer Hospital

Changsha, 410013, China
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola

Meldola, Emilia-Romagna, 47014, Italy
Instituto do Cancer do Estado de Sao Paulo - ICESP

São Paulo, São Paulo, 01246-000, Brazil
Juntendo University Hospital

Tokyo, 113-8431, Japan
Kagoshima University Hospital

Kagoshima, 890-8520, Japan
Karolinska Universitetssjukhuset, Solna

Stockholm, 171 76, Sweden
Kindai University Hospital

Osaka, 590-0197, Japan
Kobe City Medical Center General Hospital

Hyōgo, 650-0047, Japan
Korea University Guro Hospital

Seoul, 08308, South Korea
Kumamoto University Hospital

Kumamoto, 860-8556, Japan
Kurume University Hospital

Fukuoka, 830-0011, Japan
Kyungpook National University Chilgok Hospital

Daegu, 41404, South Korea
NHO Kyushu Cancer Center

Fukuoka, 811-1395, Japan
National Cancer Centre

Singapore, 168583, Singapore
Northwest Cancer Specialists, P.C.

Tigard, Oregon, 97223, United States
Oncology Unit, Faculty of Medicine, Vajira Hospital

Dusit, 10300, Thailand
One Clinical Research

Nedlands, Western Australia, 6009, Australia
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Pusan National University Yangsan Hospital

Gyeongsangnam-do, 50612, South Korea
Rajavithi Hospital

Bangkok, 10400, Thailand
RedSalud Vitacura

Santiago, Chile
Sahlgrenska University Hospital

Gothenburg, 413 45, Sweden
Seoul National University Bundang Hospital

Seongnam-si, 13605, South Korea
Shandong Cancer Hospital

Jinan, 250117, China
Shanghai Pulmonary Hospital

Shanghai, 200433, China
Songklanagarind Hospital

Songkhla, 90110, Thailand
Taichung Veterans General Hospital

Taichung, 40705, Taiwan
The Cancer Institute Hospital of JFCR

Tokyo, 135-8550, Japan
UZ Gent

Ghent, 9000, Belgium
Xinqiao Hospital of Third Military Medical University

Chongqing, 400037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.